Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREK: Ketamine-assisted psychotherapy for existential distress in GI cancer
NCT06001372Phase 1Terminated
- Sponsor
- University of Utah
- Start
- Oct 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ketamine in existential distress, major depressive disorder (MDD) and anxiety disorder, sponsored by University of Utah. Primary endpoint: Rate of Study Completion by Enrolled Participants at 2 weeks. Started Oct 2023; status: terminated.
02
Drugs
ketamine
03
Conditions
existential distressmajor depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on NCT06001372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06001372.